Sml1 is an intrinsically disordered protein inhibitor of Saccharomyces cerevisiae ribonucleotide reductase (ScRR1), but its inhibition mechanism is poorly understood. RR reduces ribonucleoside diphosphates to their deoxy forms, and balances the nucleotide pool. Multiple turnover kinetics show that Sml1 inhibition of dGTP/ADP-and ATP/CDP-bound ScRR follows a mixed inhibition mechanism. However, Sml1 cooperatively binds to the ES complex in the dGTP/ADP form, whereas with ATP/CDP, Sml1 binds weakly and noncooperatively. Gel filtration and mutagenesis studies indicate that Sml1 does not alter the oligomerization equilibrium and the CXXC motif is not involved in the inhibition. The data suggest that Sml1 is an allosteric inhibitor.
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Keywords: enzyme kinetics; intrinsically disordered protein; mixed inhibition; nucleotides; oligomerization Ribonucleotide reductase (RR) catalyzes the conversion of ribonucleotides to 2ʹ-deoxyribonucleotides, which is the rate determining step of dNTP synthesis. Allosteric regulation of RR substrate specificity and overall activity is essential for maintaining balanced and adequate deoxynucleotide pools during S-phase [1] . In other phases of the cell cycle, RR activity is also regulated at the level of transcription [2] and subunit localization [3] , and in the case of Saccharomyces cerevisiae RR (ScRR) and recently discovered in human RR (hRR), activity is limited by small protein inhibitors, Sml1 (suppressor of mec-1 lethality) and IRBIT, respectively [4] [5] [6] . Sml1 is believed to down-regulate ScRR activity through interactions with the catalytic subunit, but the mechanism by which it functions to block activity is unknown [4, 5, [7] [8] [9] [10] . Here, we report multiple turnover inhibition kinetics and biochemical analyses of Sml1 that demonstrate a pattern of inhibition that depends on the identity of the allosteric regulator bound to the enzyme. Together the results suggest a mechanism in which effector binding modulates the affinity and cooperativity of Sml1, which may act to modulate down-regulation of ScRR activity during the cell cycle.
ScRR is representative of eukaryotic RR and consists of a multimeric catalytic a-subunit [a = n where n = 2, 4 or 6] and a heterodimeric complex comprised of two bsubunits (bb 0 heterodimers [bb 0 = m, m = 1, 2 or 3], where the b 0 -subunit lacks the key residues required for generating the catalytic free radical) [11] . The a-subunit contains Abbreviations A-site, activity site; C-site, catalytic site; CXXC, C-terminal motif; dNDPs, deoxyribonucleoside 5 0 -diphosphates; dNTPs, deoxyribonucleotide triphosphates; NDPs, ribonucleoside 5 0 -diphosphates; RR, ribonucleotide reductase; ScRR, Saccharomyces cerevisiae ribonucleotide reductase; ScRR1, subunit of Saccharomyces cerevisiae ribonucleotide reductase; SEC, size exclusion chromatography; S-site, specificity site; TR, thioredoxin.
two different nucleotide binding sites that allosterically regulate substrate specificity and overall activity (Fig. 1A ) [1, 12] . Binding of ATP, dATP, dGTP, or dTTP to the allosteric specificity site (S-site) induces a-subunit dimers and determines the preference for NDP substrates binding to the catalytic site (C-site) where reduction of the 2ʹOH occurs (Fig. 1A ) [1, [12] [13] [14] [15] [16] [17] . A second allosteric site, termed the activity site (A-site), regulates the overall activity of the enzyme by binding either the allosteric activator ATP or the allosteric inhibitor dATP, eliciting the formation of either active or inactive RR a-subunit hexamers, respectively (Fig. 1A ) [1, 12, [14] [15] [16] [18] [19] [20] [21] . Both modes of regulation of RR are central to the maintenance of a balanced pool of dNTPs during DNA synthesis [18, 22] .
ScRR activity is also under tight regulation by the small protein inhibitor Sml1. Sml1 is a 104 amino acid protein which is intrinsically disordered; and levels of Sml1 fluctuate throughout the cell cycle, diminishing when DNA synthesis or repair is needed [5, 7, 23, 24] . The cellular concentration of Sml1 is regulated by phosphorylation which leads to ubiquination-dependent degradation [8, [23] [24] [25] [26] [27] [28] [29] . Sml1 is known to bind to the a-subunit, but little else is known regarding the mechanism by which it inhibits ScRR [4, 5, [7] [8] [9] [10] . The ability of RR to exist in multiple allosterically regulated forms raises the question of whether these states have differential sensitivity to inhibition by Sml1. 
Materials and methods

Expression and purification of recombinant proteins
Saccharomyces cerevisiae a-subunit (ScRR1) protein, bbʹ-subunit (ScRR2ScRR4), and Sml1 were expressed and purified as described [15, 30, 31] . Yeast thioredoxin (TR) and thioredoxin reductase (TRR) were a gift from Dr. Sang Won Kang (Ewha Womans University, Seoul, Korea). Yeast TR and TRR protein were expressed and purified using the method adapted from Kim et al. [32] . DCXXC deletion mutant was prepared using the forward primer-5 0 -CA GAAGCTTGAGAAATGTGTTC-3 0 and reverse primer-
purification, and biochemical characterization of DCXXC ScRR1 is equivalent to that of wild-type ScRR1.
Labeling of mutant S60C Sml1
Sml1 containing a fluorescence tag was prepared as described in reference [33] . All fluorescent studies were done with Cys 
Size exclusion chromatography
Gel filtration was performed as described in references [16, 33] . All SEC work was carried out using a Superdex 200 10/300 GL column (GE Lifesciences, Piscataway, NJ, USA). ATP/dATP-induced oligomers of ScRR1 were analyzed in the presence of 3 mM ATP/50 lM dATP. The dATP hexamer-Sml1 complex was prepared by incubating 10 lM of ScRR1 and 50 lM dATP for 10 min and then by adding 40 lM of Ser 60 Cys Sml1 to a final volume of 100 lL. The resulting mixture was further incubated for 10 additional minutes on ice. For the ATP hexamer-Sml1 complex, we used 3 mM ATP but used the same order of additions and incubation times as with the 50 lM dATP hexamer complex.
Enzyme assays
The steady-state kinetics of ScRR were measured in the presence and absence of Sml1 in vitro using [
3 H]CDP and
]ADP reduction assays as described [16] , using 0.5 lM ScRR1 dimer and 5 lM ScRR2•ScRR4 heterodimer. The radiolabeled dNDP products were separated from unreacted NDP substrates using borate chromatography and quantified by isotope counting [16] . When ATP/CDP was used as the effector-substrate pair, [ Enzyme inhibition experiments performed in the presence of TR instead of DTT consisted of the same assay design as WT except for the substitution of the TR system (100 lM TR, 1 lM TRR, 2 mM NADPH) in place of DTT. Prior to activity assay experiment, a dialysis of the ScRR1 sample was performed to remove DTT, which is needed for purification and storage purposes.
Analysis of steady-state inhibition kinetics
To investigate the mechanism of Sml1 inhibition, we the evaluated steady-state ScRR reaction kinetics measured at a range of Sml1 and NDP substrate concentrations in the context of a general equilibrium model for mixed inhibition (Scheme 1).
To characterize the inhibition mechanism and estimate the apparent inhibitor affinity for E and ES as well as the cooperativity of binding to these two enzymes forms, the steady-state inhibition data were globally fit to a general rate equation for mixed inhibition (further description of derivation in supplemental text),
in which K i is the affinity of Sml1 to the free enzyme (E in Scheme 1) and aK i is the affinity for the ES complex such that the value a measures the difference in affinity of Sml1 for these two enzyme forms. In Scheme 1, the parameter n is the stoichiometry of Sml1 binding to RR. In equation 1, n E and n ES are used as variables to evaluate cooperativity of binding of Sml1 to the free (E) and substrate-bound (ES) forms of the enzyme, respectively. The data were first fit to a model in which a = 1 to evaluate a purely noncompetitive mechanism. However, a value less than 1 Scheme 1. General scheme for mixed inhibition of RR (E) by Sml1 (I).
provided a better fit to the data. Models in which n E = n ES = 1 were subsequently evaluated and as discussed in the text, this model describes the inhibition mechanism of Sml1 inhibition of the ATP-bound form of the enzyme. Integer values of n E and n ES greater than 1 were also individually tested for the dGTPbound form of the enzyme and the goodness of fit was evaluated by comparing the magnitude of the squared differences between model and experimental data.
Results and Discussion
Steady-state kinetic analysis of the modes of ScRR1 inhibition by Sml1
Dimerization of RR is induced by binding of the effectors dGTP, dTTP, dATP, and ATP to the S-site, while binding of ATP to the A-site occurs with lower affinity and induces the formation of RR a-subunit hexamers [1, [13] [14] [15] [16] [17] . To gain information on the interaction of Sml1 with these different allosteric states, we first analyzed inhibition of the dimeric, dGTP-bound state of ScRR, which has specificity for ADP as a substrate. Linear fit of the steady-state inhibition data on double reciprocal plots, 1/v obs versus 1/[S], indicates that both the k cat /K m and k cat are affected by the presence of Sml1, and the slope (1/(k cat /K m ) and y-intercept increase as a function of Sml1 concentration (Fig. 1B) . This result demonstrates that Sml1 functionally interacts with both free enzyme (E) and the enzyme-substrate complex (ES). The double reciprocal plot also reveals that the decrease in k cat (increase in 1/v obs intercept) with increasing concentrations of Sml1 is nonlinear, suggesting that the binding of Sml1 to the ES complex is cooperative. Plots of the y-intercept (1/k cat ) versus Sml1 concentration illustrate the exponential dependence of the effect of inhibitor concentration on k cat (Fig. 1E) . In contrast, the interaction of Sml1 with free E appears to be noncooperative. A plot of the slope (1/(k cat /K m )) versus Sml1 concentration shows linear dependence of k cat /K m on Sml1 concentration (Fig. 1F) . Global fitting of the steady-state inhibition data to a general rate equation for mixed inhibition, as described in Materials and Methods, was used to evaluate different potential mechanistic possibilities for the dimeric, dGTP-bound state of ScRR (Fig. 1B inset,  Fig. S1A ). The simplest model consistent with the data involves noncooperative binding of Sml1 to the free enzyme with a K i of 0.8 AE 0.12 lM. Fitting the data, assuming tighter or weaker binding of Sml1 to ES relative to E (a < or > 1), indicated that the data were best described by a mixed inhibition model in which Sml1 binds to ES with the tighter affinity (aK i = 0.18 AE 0.03 lM) than E. Interestingly, the data are best described by a mechanism assuming cooperativity of Sml1 binding to the ES complex (n ES = 2). This observation is consistent with interpretations from inspection of the double reciprocal plot.
Next, we compared the mode of inhibition of the hexameric, ATP-bound form of ScRR by Sml1, which has specificity for CDP as a substrate. As shown by double reciprocal plots of the linear fit (Fig. 1C) , Sml1 has a smaller effect on the k cat /K m and k cat of this ATP-bound allosteric state over the range of CDP concentrations tested, in comparison to the dimeric dGTP state. Unlike the dimeric dGTP-bound state of ScRR, a plot of the observed intercepts and slopes [1/k cat and 1/(k cat /K m )] versus inhibitor concentration are both linear (Fig. 1E-F) . This result is consistent with noncooperative binding of Sml1 to both E and ES. Global fitting of these data to general rate equation reveals a 10-fold difference in binding affinity of Sml1 to E and ES, 20 AE 5.6 lM and 2 AE 0.59 lM, respectively (Fig. 1C inset, Fig. S1B ). These binding affinities are significantly lower relative to the dimeric dGTP-bound ScRR. The substantial difference in the binding affinity to E and ES, with the apparent preference for ES indicates that Sml1 binding to the ATP/ CDP-bound ScRR also follows a mixed inhibition model. Most importantly, the global fitting further illustrated that the data are consistent with a model involving noncooperative binding of Sml1 to both E and ES (n E = n ES = 1).
Two different patterns of ScRR inhibition by Sml1 are observed depending on if dGTP or ATP is bound in the S-site to allosterically regulate ScRR substrate specificity. However, these two reaction conditions also differ in the oligomerization state of the enzyme as ATP binding at the A-site induces hexamerization of RR a-subunit. To determine the extent to which oligomerization or the identity of the allosteric effector bound to the S-site correlate with the mode of Sml1 inhibition, we compared the inhibition of the hexameric dGTP-bound form in the presence of ATP to induce hexamer formation. Linear fit on a double reciprocal plot indicates visual similarity with the dimeric dGTP ScRR double reciprocal plot (Fig. 1D) . Plot of the intercept versus Sml1 concentration shows there is an exponential dependence of the effect of inhibitor concentration on k cat , indicating cooperative binding of Sml1 to ES (Fig. 1E) . As also seen with both the dimeric dGTP and the hexameric ATP/CDP, interaction of Sml1 with E appears to be noncooperative (Fig. 1F) . Global fitting analysis of the data for the ATP/dGTP-bound form of ScRR shows inhibition can be described by a mixed inhibition model in which Sml1 binds to E with a K i of 0.18 AE 0.03 lM and binds cooperatively (n ES = 2) to ES with a aK i of 0.07 AE 0.01 lM (Fig. 1D inset, Fig. S1C ). This analysis is consistent with expectations from inspection of the double reciprocal plot (Fig. 1D) .
Examination of the inhibition kinetics of ScRR by Sml1 is relatively complex as it does not easily fit with a classic mechanism of inhibition: competitive, noncompetitive, or uncompetitive, but rather fits a mixed inhibition mechanism with specific aspects of this mechanism dependent on the allosteric state of the enzyme. Visual inspection of the double reciprocal plots clearly shows that Sml1 does not exclusively act by competitively inhibiting ScRR. All allosteric states exhibit a k cat change with increase in Sml1 concentration, indicating that Sml1 is not competing with the substrate, ADP or CDP, for binding at the C-site. It can also be argued that none of the allosteric states tested follow a purely noncompetitive mechanism. Classical noncompetitive mechanism exhibits equal affinity for E and ES with no cooperativity. Attempts to fit this mechanism to the inhibition data proved to be unsuccessful. For the dimeric and hexameric ADP forms, the data fit a mixed inhibition model where there is a higher affinity for the ES than the E, 4.5-and 2.5-fold difference in affinity, respectively. In the case of CDP, it can be said that it is a mixed inhibition mechanism as there is affinity for both the ES and E, but with greater affinity for ES (10-fold greater). Thus, an important shared attribute of all allosteric forms of ScRR is that there is a higher affinity for the ES than E. It is possible that the structural change in ScRR1 specifically induced by substrate binding allows for better exposure of the Sml1-binding site for a stronger binding affinity. The differences in the structure of ScRR1 when bound to either ADP or CDP might explain why different inhibition mechanisms are observed.
Sml1s effect on oligomerization
The steady-state inhibition supports functional binding of Sml1 to both E and ES in order to inhibit ScRR activity and the binding changes observed vary based on substrate and oligomerization states. So the question remains whether or not Sml1 was binding to the dimer or hexamer forms described in the kinetic assays as expected and whether inhibition by Sml1 binding can be further explained by changes in oligomerization. It is possible that the differences in binding to these different allosteric forms of the enzyme could reflect thermodynamic or mechanistic linkage between Sml1 binding and oligomerization. Therefore, size exclusion chromatography was used to test whether Sml1 forms stable complexes with dimeric and hexameric forms of ScRR a-subunit and examine its effect on oligomerization (Fig. 2) . Fluorescently labeled Sml1 was incubated with ScRR hexamers formed in the presence of both dATP and ATP ( Fig. 2A-B) . Although it is not possible to maintain equilibrium conditions during chromatographic separation, the data clearly show that Sml1 forms stable complexes with ScRR dimers and hexamers (Fig. 2) . Sml1 binds to both active (ATP bound) and inactive (dATP bound) hexamers ( Fig. 2A-B) and does not appear to result in major alteration of the oligomerization equilibrium under conditions used in enzyme assays (Fig. 2C-D) .
Biochemical data are consistent with the functional association of Sml1 with both the free (E) and substrate-bound (ES) forms of ScRR. Sml1 binding to the hexameric form of ScRR1 does not disrupt these hexamers, while Sml1 binding to the dimeric form does not shift the oligomerization equilibrium toward hexamer formation. Together this further supports the conclusions from the kinetic data that binding and inhibition of ScRR1 by Sml1 is determined by allosteric state of ScRR, but the inhibition is not due to a shift in equilibrium of ScRR1 oligomeric state. The physiological role of Sml1, as supported by its stable binding to both ATP and dATP hexamers, can be attributed to complimenting the allosteric inhibition of dATP. In vitro studies indicate dATP inhibits ScRR by 50% compared to ATP-bound ScRR under physiological conditions, while the addition of Sml1 leads to the complete inhibition of ScRR (Fig. S2 ).
Sml1 and the regeneration of the active site of ScRR1
It has been hypothesized that Sml1 might interfere with the reduction pathway in ScRR, targeting the CXXC motif located at the C terminus of the a-subunit (ScRR1), an intermediate in the thioredoxin (TR) reduction pathway [9, 34] . In other words, does Sml1 inhibit ScRR by interfering with the rate limiting step of enzyme regeneration? After a catalytic cycle, the oxidized cysteines in the C-site require reduction prior to the next catalytic cycle. TR, one of the main reductants used in this process cannot directly reduce these cysteines so the intermediate, CXXC motif, is utilized. TR transfers a reducing equivalent to the CXXC motif and the flexible C-terminal tail then interacts with the cysteines in the C-site to transfer this reducing equivalent [34] . Removal of this CXXC motif renders the enzyme unable to be reduced naturally, but for experimental purposes, the synthetic two-electron reductant, DTT, can be used as the reductant, whose small size allows for the reduction of the active site directly [35] . To investigate the possibility that Sml1 is targeting the reduction pathway, the CXXC motif was removed and DTT was utilized. RR activity assay was utilized to measure the enzymatic activity levels of ScRR as determined by the amount of product formed, [ 14 
C]
ADP in this study. Measurement of the activity of WT and DCXXC mutant in the presence of DTT were used as controls to test that the mutant was functional, and the results indicate that the DCXXC mutant activity was similar to WT (Fig. 3) . Activity in WT ScRR1 in the presence of Sml1 and either DTT or TX indicated that Sml1 can inhibit product production of ScRR1 despite which reductant is present. In both cases, there was essentially no product formation (Fig. 3) . The key experimental condition, however, was the DCXXC mutant in the presence of Sml1 and DTT. Two main possibilities were anticipated in this [
14 C]ADP reduction experiment; either (1) there would be retention of activity with DTT and the mutant in the presence of Sml1, indicating Sml1 is targeting the CXXC motif, or (2) there would be a loss of activity, indicating that Sml1 is not targeting the CXXC motif but rather another site. Results indicate that there was no [
14 C]ADP reduction with DCXXC ScRR1 in the presence of DTT and 1 lM of Sml1 (Fig. 3) .
Through this investigation of Sml1 targeting the CXXC motif at the C terminus of ScRR1, we have observed that Sml1 inhibition is independent of this motif. While we cannot rule out that Sml1 interferes elsewhere in the reduction pathway of ScRR1, it is important to know that Sml1 is not binding at the C terminus. It is binding elsewhere on ScRR1 which might be causing a structural conformational change to prevent DTT-mediated dNDP production. Without structural data of this complex, it is hard to distinguish precisely where Sml1 is binding on ScRR, eliciting either medium-or long-range interactions. Structural studies are currently being pursued to determine specifically how Sml1 is binding to inhibit ScRR activity.
Conclusions
Considering the importance of RR in maintaining an adequate and balanced cellular dNTP pool for the high fidelity of DNA replication and repair, the study of RR regulation has become a focus of attention for pharmacological intervention. The inhibition of budding yeast RR (ScRR) by Sml1 is one of the few examples of a natural protein RR inhibitor, making it a great research target for the development of future pharmacological interventions against cancer and other diseases characterized by rapidly dividing cells. One of the key characteristics of Sml1 that still remains a mystery is its mechanism of inhibition, which may help us structurally understand Sml1 as an intrinsically disordered protein and how it interacts with ScRR1. The data presented here are most consistent with a model in which Sml1 acts as an allosteric inhibitor of ScRR catalysis, exhibiting different affinity in the presence and absence of effector-substrate pair and different mechanisms depending on the substrate bound (Fig. 4) . It can be argued that the difference in binding between effector/ substrate pairs seen here is simply because of the It has been in debate since the discovery of Sml1 whether there is a human analog and whether studying Sml1 is important. Recently there was the discovery of IRBIT, a proposed human analog of Sml1 [6] . While the discovery of IRBIT is recent and there have not been extensive studies on this inhibitor, there are some similarities between IRBIT and Sml1. Both IRBIT and Sml1 further decrease the activity of RR compared to inhibition by dATP alone, with the distinction that IRBIT stabilizes only the dATP hRRM1 hexamer [6] and Sml1 has been shown to fully inhibit both the ATP and the dATP hexamer of ScRR. It was also noted that structurally, the N-terminal domain of IRBIT belongs to a class of IDPs (intrinsically disordered proteins) similar to Sml1 [6] . Similarly, p53R2 is known to make several protein-protein interactions of functional importance [36, 37] . The discovery of IRBIT validates the importance of studying Sml1 for the development of antiproliferative therapeutics.
